Vor Biopharma (VOR) Price & Analysis

Q: What was Vor Biopharma’s price range in the past 12 months?

Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.

Q: What is Vor Biopharma’s market cap?

Vor Biopharma’s market cap is $179.23M.

Q: When is Vor Biopharma’s upcoming earnings report date?

Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 98 days.

Q: How were Vor Biopharma’s earnings last quarter?

Vor Biopharma released its earnings results on Nov 13, 2025. The company reported -$121.63 earnings per share for the quarter, missing the consensus estimate of -$3.452 by -$118.178.

Q: Is Vor Biopharma overvalued?

According to Wall Street analysts Vor Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Vor Biopharma pay dividends?

Vor Biopharma does not currently pay dividends.

Q: What is Vor Biopharma’s EPS estimate?

Vor Biopharma’s EPS estimate is -1.88.

Q: How many shares outstanding does Vor Biopharma have?

Vor Biopharma has 21,910,630 shares outstanding.

Q: What happened to Vor Biopharma’s price movement after its last earnings report?

Vor Biopharma reported an EPS of -$121.63 in its last earnings report, missing expectations of -$3.452. Following the earnings report the stock price went up 2.667%.

Q: Which hedge fund is a major shareholder of Vor Biopharma?

Currently, no hedge funds are holding shares in VOR

Compare

944 Followers

VOR Stock Chart & Stats

$8.36

<$0.01(<0.01%)

At close: Jan 08 4:00 PM EST

$8.36

<$0.01(<0.01%)

Day’s Range― - ―

52-Week Range$2.63 - $65.80

Previous CloseN/A

Volume424.02K

Average Volume (3M)816.35K

Market Cap

$179.23M

Enterprise Value$158.13M

Total Cash (Recent Filing)$170.46M

Total Debt (Recent Filing)$3.06M

Price to Earnings (P/E)―

Beta4.90

Next Earnings

Mar 19, 2026

EPS Estimate

-1.88

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-121.63

Shares Outstanding21,910,630

10 Day Avg. Volume412,202

30 Day Avg. Volume816,353

Financial Highlights & Ratios

PEG Ratio0.23

Price to Book (P/B)0.79

Price to Sales (P/S)0.00

P/FCF Ratio-0.76

Enterprise Value/Market Cap0.88

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-93.57

Enterprise Value/Ebitda-0.14

Forecast

1Y Price Target

$40.60

Price Target Upside385.65% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)-108.75

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentTelitacicept has achieved multiple regulatory approvals and treated over 70,000 patients, suggesting potential for success in larger global markets.

Financial StrategyVor Bio now has the required capital to fund a global Phase 3 study in Sjögren's disease (SjD).

Leadership And ManagementRecent executive additions, including a Chief Development Officer with a successful track record, boost confidence in the leadership team's ability to drive long-term value creation.

Bears Say

Clinical ChallengesThe robust placebo-adjusted score in the China study with telitacicept may be a high bar to replicate in a broader patient population with a potentially different study protocol.

Market CompetitionThe competitive landscape for dual BAFF/APRIL antagonists is becoming increasingly dense, with several competitor molecules in development.

Stock ValuationVor shares declined sharply as the offer price of $10.00 was a ~47% discount to the prior closing price, $18.80.

Vor Biopharma News

Vor Bio initiated with an Overweight at JPMorgan

JPMorgan initiated coverage of Vor Bio (VOR) with an Overweight rating and $43 price target The firm sees...

2d ago

VOR

Vor Bio assumed with a Neutral at Wedbush

Wedbush analyst Martin Fan assumed coverage of Vor Bio (VOR) with a Neutral rating with a price target...

16d ago

VOR

Vor Bio price target lowered to $32 from $55 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Vor Bio (VOR) to $32 from $55 and keeps a...

27d ago

VOR

Vor Bio 10M share Spot Secondary priced at $10.00

The deal priced at low end of $10.00-$12.00 range. JPMorgan, Jefferies, Citi and TD Cowen are acting as...

30d ago

VOR

Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs

Anupam Rama, an analyst from J.P. Morgan, has initiated a new Buy rating on Vor Biopharma (VOR). Anupam...

2d ago

VOR

Vor Biopharma Approves Stock Option Repricing Plan

Vor Biopharma ( ($VOR) ) has provided an announcement. On December 5, 2025, Vor Biopharma‘s board approved a...

2d ago

VOR

Vor Biopharma Reports Q3 2025 Financial Results and Strategic Updates

Vor Biopharma, Inc. ( ($VOR) ) has released its Q3 earnings. Here is a breakdown of the information...

23d ago

VOR

Vor Biopharma Announces $93.7 Million Public Offering

Vor Biopharma ( ($VOR) ) has provided an announcement. On November 10, 2025, Vor Biopharma Inc. announced an...

29d ago

VOR

Vor Bio $100M Spot Secondary; price range $10.00-$12.00

JPMorgan, Jefferies, Citi and TD Cowen are acting as joint book running managers for the offering. Published first...

1M ago

VOR

Vor Bio announces $100M common stock offering

Vor Bio (VOR)pharma announced that it has commenced an underwritten public offering of $100M of shares of its...

1M ago

VOR

Vor Bio achieves primary endpoint in Stage A of Phase 3 study of telitacicept

Vor Bio (VOR) announced that the primary endpoint was achieved in Stage A of a Phase 3 clinical...

1M ago

VOR

Vor Biopharma Appoints New Chief Medical Officer

The latest announcement is out from Vor Biopharma ( ($VOR) ). On November 2, 2025, Vor Biopharma Inc....

1M ago

VOR

Vor Bio appoints Sokolove as Chief Medical Officer

Vor Bio (VOR) announced the appointment of Jeremy Sokolove, M.D., as Chief Medical Officer. Most recently, Dr. Sokolove...

1M ago

VOR

ROIV

Vor Bio says telitacicept shows sustained efficacy in China Phase 3 study

Vor Bio (VOR) announced that its collaborator, RemeGen Co., presented 48-week open-label extension data from its Phase 3...

1M ago

VOR

VOR FAQ

What was Vor Biopharma’s price range in the past 12 months?

Vor Biopharma lowest stock price was $2.63 and its highest was $65.80 in the past 12 months.

What is Vor Biopharma’s market cap?

Vor Biopharma’s market cap is $179.23M.

When is Vor Biopharma’s upcoming earnings report date?

Vor Biopharma’s upcoming earnings report date is Mar 19, 2026 which is in 98 days.

How were Vor Biopharma’s earnings last quarter?

Vor Biopharma released its earnings results on Nov 13, 2025. The company reported -$121.63 earnings per share for the quarter, missing the consensus estimate of -$3.452 by -$118.178.

Is Vor Biopharma overvalued?

According to Wall Street analysts Vor Biopharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Vor Biopharma pay dividends?

Vor Biopharma does not currently pay dividends.

What is Vor Biopharma’s EPS estimate?

Vor Biopharma’s EPS estimate is -1.88.

How many shares outstanding does Vor Biopharma have?

Vor Biopharma has 21,910,630 shares outstanding.

What happened to Vor Biopharma’s price movement after its last earnings report?

Vor Biopharma reported an EPS of -$121.63 in its last earnings report, missing expectations of -$3.452. Following the earnings report the stock price went up 2.667%.

Which hedge fund is a major shareholder of Vor Biopharma?

Currently, no hedge funds are holding shares in VOR

Vor Biopharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

51.94%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Vor Biopharma

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Vor Biopharma (VOR) Earnings & Revenues

Historic Earnings Reports

VOR Stock 12 Month Forecast

Average Price Target

$40.60

▲(385.65% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","34":"$34","65":"$65","18.5":"$18.5","49.5":"$49.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$9.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,18.5,34,49.5,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,27.178461538461537,30.246923076923075,33.315384615384616,36.38384615384615,39.45230769230769,42.52076923076923,45.58923076923077,48.65769230769231,51.72615384615385,54.79461538461538,57.863076923076925,60.931538461538466,{"y":64,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,25.378461538461536,26.646923076923077,27.915384615384614,29.183846153846154,30.45230769230769,31.72076923076923,32.98923076923077,34.25769230769231,35.526153846153846,36.79461538461538,38.06307692307692,39.33153846153846,{"y":40.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,24.11,22.947692307692307,21.785384615384615,20.623076923076923,19.46076923076923,18.298461538461538,17.136153846153846,15.973846153846154,14.811538461538461,13.649230769230769,12.486923076923077,11.324615384615385,10.162307692307692,{"y":9,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":18.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.48,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.1,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.38,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.4,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.69,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.26,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.11,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >